• Ann. Intern. Med. · Mar 2024

    Clinical Trial

    In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.

    • Ahmad Masri and Van SpallHarriette G CHGCMcMaster University, Hamilton, Ontario, Canada (H.G.V.)..
    • Oregon Health & Science University, Portland, Oregon, USA (A.M.).
    • Ann. Intern. Med. 2024 Mar 1; 177 (3): JC30JC30.

    AbstractMaurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916.

      Pubmed     Copy Citation  

      Add institutional full text...

    Notes

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.